Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rifampicin population pharmacokinetics and pharmacogenomic evaluation of SLCO1B1 gene in tuberculosis patients.

The Indian journal of tuberculosis - 1 Apr 2026

Lomash Avinash, Roy Vandana, Daniel Shilpa, Naeem Syed Shariq, Kapoor Seema, Khanna Ashwani, Daga Mradul Kumar

Abstract excerpt

BACKGROUND: Rifampicin (RMP) is a key drug in the standard anti-tubercular regime. Variations in the SLCO1B1 gene are reported to influence RMP blood levels in tuberculosis patients. Association between SLCO1B1 gene and RMP concentration in tuberculosis patients was evaluated. METHOD: RMP blood levels were determined at 0,1, 2,3,4,6,8,12 h after administration in 72 patients. Population pharmacokinetic (PopPK)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antitubercular
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver-Specific Organic Anion Transporter 1

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Share to Rifampin

Share to Tuberculosis

Share to Young Adult

Source

Identifiers

PMID: 42031461
DOI: 10.1016/j.ijtb.2025.07.006

Genes

SLCO1B1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rifampicin population pharmacokinetics and pharmacogenomic evaluation of SLCO1B1 gene in tuberculosis patients.PMID 42031461Read ↗

A population approach of rifampicin pharmacogenetics and pharmacokinetics in Mexican patients with tuberculosis.Semantic proximity Read ↗

Relationship among genetic polymorphism of SLCO1B1, rifampicin exposure and clinical outcomes in patients with active pulmonary tuberculosis.Semantic proximity Read ↗

Transporter and metabolizer gene polymorphisms affect fluoroquinolone pharmacokinetic parametersSemantic proximity Read ↗

SLCO1B1 and SLC10A1 polymorphism and plasma rifampin concentrations in patients with co-morbidity tuberculosis-diabetes mellitus in Baja California, Mexico.Semantic proximity Read ↗

Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis.Semantic proximity Read ↗

Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TB-rifampicin sensitivity among Ugandan patients.Semantic proximity Read ↗

SLCO1B1 gene polymorphisms do not influence plasma rifampicin concentrations in a South Indian population.Semantic proximity Read ↗

Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.Semantic proximity Read ↗

Influence of Single Nucleotide Polymorphisms on Rifampin Pharmacokinetics in Tuberculosis PatientsSemantic proximity Read ↗

Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis.Semantic proximity Read ↗

Polymorphisms of SLCO1B1 Gene in Sundanese Ethnic Population of Tuberculosis Patients in Indonesia.Semantic proximity Read ↗

Exploring Variability in Rifampicin Plasma Exposure and Development of Anti-Tuberculosis Drug-Induced Liver Injury among Patients with Pulmonary Tuberculosis from the Pharmacogenetic PerspectiveSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.